Second national grant strengthens company’s expanding global IP estate More: Poolbeg secures Canadian patent for POLB 001 in cancer immunotherapy‑induced CRS Source: News
read moreCSL has slashed its revenue projection for the fiscal year from $15.8 billion to $15.2 billion, in another indication of the Australian company’s financial distress since its 2022 acquisition of Vifor Pharma for $11.7 billion. Additionally, the Australian company is
read moreWith the program’s seventh approval in the books, the FDA is illustrating just how speedy it can be with drug reviews that fall under its U.S. national priority pilot. More: Partner's bispecific Bizengri nabs FDA national priority nod in rare
read moreDaiichi Sankyo aims to transform its antibody-drug conjugate leadership into a top global oncology standing. In a new five-year business plan unveiled Monday, the Japanese pharma outlined a roadmap to become a global top five oncology player by 2035, plus
read more
Early safety and efficacy signals support move into repeat‑dose phase 2a trial More: Pulsesight reports positive phase 1 data for PST‑611 in dry AMD Source: News
read moreOVID Health has hired former Edelman global public health lead Davide Scalenghe to expand the agency’s international strategy and partnerships work. More: OVID Health hires Edelman alum Davide Scalenghe to boost its international footprint Source: fierce
read more© 1994 - 2026 B.M. Pharmaceuticals